Shareholders of Molecular Partners AG approved all Board proposals at the Annual General Meeting
Zurich-Schlieren, May 06, 2015. At today’s Annual General Meeting of Molecular Partners AG (ticker: MOLN), the shareholders of the company approved all motions proposed by the Board of Directors with a large majority.
The shareholders of Molecular Partners AG approved the annual report and the annual financial statements for the financial year 2014, as well as the appropriation of the 2014 results. The Board of Directors and the Management Board were granted discharge for the financial year 2014.
Jörn Aldag, Goran Ando, Francesco De Rubertis, Steven H. Holtzman, William A. Lee, Andreas Plückthun, Petri Vainio and Christian Zahnd were all re-elected as members of the Board of Directors and Jörn Aldag was also re-elected as Chairman of the Board of Directors of Molecular Partners AG. The proposed three members of the Compensation Committee – Jörn Aldag, William A. Lee and Petri Vainio – were also re-elected.
The shareholders of Molecular Partners AG also approved the proposed respective com-pensation amounts for the Board of Directors and the Management Board.
About Molecular Partners AG
Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new powerful class of therapies known as DARPins™. DARPins™ are potent, specific and versatile small protein thera-pies which have the potential to offer benefits over conventional monoclonal antibodies or other current-ly available protein therapeutics. The DARPin technology has the potential to enable a “multi-benefit” approach to treatment which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins™ have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. Its most ad-vanced product candidate is abicipar pegol, for which the company’s partner Allergan plans to initiate a Phase III clinical trial in wet AMD in 2015. The company has ongoing research and development partner-ships with leading pharmaceutical companies including Allergan, Roche and Janssen and is backed by established biotech investors.
For further details, please contact:
-+41 (0)43 344 4242
Dr. Christian Zahnd, CEO
Dr. Patrick Amstutz, COO
Tel: +41 (0) 44 755 77 00
This announcement is not an offer to sell, or a solicitation of an offer to purchase, any securities of Molecular Partners AG (the “Company”), nor shall it or any part of it form the basis of, or be relied on in connection with any contract or investment decision. This announcement is not for publication or distribution (directly or indirectly) in or to the United States, Canada, Australia, Japan or any other jurisdiction in which such distribution would be unlawful.
This announcement contains statements that are, or may be deemed to be, forward-looking statements. In some case, these forward-looking statements can be identified by the use of forward-looking terminology or subjective assessments, including the words “potential”, “expects”, “targets”, “designed”, “intends” or “plans” or comparable terminology or by discussions of plans, objectives, targets, goals, future events or intentions. These forward-looking statements include matters that are not historical facts or which may not otherwise be provable by reference to past events, and are based on assumptions. By their nature, forward-looking statements are subject to known and unknown risks and uncertainties because they relate to events and/or depend on circumstances that may or may not occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of the Company cannot be relied on as a guide to future performance.
The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. Neither the Company nor any other person undertakes any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.